Prophylactic DNA immunization against multiple papillomavirus types

This publication has 31 references indexed in Scilit:

• Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
  Vaccine, 2006
• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
  The Lancet Oncology, 2005
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
  The Lancet, 2004
• Classification of papillomaviruses
  Virology, 2004
• Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
  New England Journal of Medicine, 2003
• Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
  British Journal of Cancer, 2003
• Papillomaviruses and cancer: from basic studies to clinical application
  Nature Reviews Cancer, 2002
• Structure of Small Virus-like Particles Assembled from the L1 Protein of Human Papillomavirus 16
  Published by Elsevier ,2000
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
  The Journal of Pathology, 1999